How to Buy Insmed Stock
Insmed Inc
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions.
Insmed stock last closed at $116.10, up 1.48% from the previous day, and has decreased 39.51% in one year. It has overperformed other stocks in the Biotechnology industry by 0.57 percentage points. Insmed stock is currently +28.44% from its 52-week low of $90.39, and -45.43% from its 52-week high of $212.75.
As of Nov 9, 2026, there are 219.38M shares of INSM outstanding. The market cap of INSM is $25.47B. In the past 24 hours, 2.67M INSM shares were traded.
How to Buy Insmed Stock
Wondering how to invest in Insmed stock? Here's how.
- Figure out where to buy Insmed stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Insmed stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Choose your method of payment and add your information.
- Analyze Insmed stock: The Insmed ticker symbol is INSM. Is Insmed stock a good investment? Should you buy shares of INSM? How do INSM's underlying business fundamentals look? Do top analysts think Insmed is a good buy? Why has INSM's stock price moved recently? (Hint: Our stock market analysis website can help you understand if INSM is a good stock to buy).
- Place your INSM buy order: Decide if you will purchase INSM shares at the current market price or use a limit order to purchase INSM shares at a given price.
- Get updates on your investment in INSM: Create a watchlist to key updates about your investment in Insmed stock.
Step 1: Figure out where to buy Insmed stock
You will need a brokerage account to access the NASDAQ market and buy INSM stock.
Our favorite brokerage: eToro
Based on our experience, eToro is the best brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Technology to Real Estate, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal details so you can buy INSM stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to open a new trading account.
- Send your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have filled out your info on the best stock broker app, your next step is to transfer the money for your investment:
Watch the video below for more details transferring funds into your brokerage account.
Step 4: Analyze Insmed stock
Once you have identified the best place to buy Insmed stock, it's very important to evaluate their stock prior to buying, so you actually comprehend the risk as well as the upside.
Insmed shares at a glance
INSM Due Diligence Checks
WallStreetZen was created to help average investors perform better fundamental analysis.
You can view all of the due diligence checks on INSM's stock page.
Is INSM stock undervalued or overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge INSM's fair value.
Using relative valuations metrics:
- INSM could be overvalued based on its P/B ratio of 35.07x, relative to Biotechnology industry P/B ratio of 5.33x
You can do more valuation analysis on INSM's stock here.
Is INSM a healthy company?
Passed Financial Due Diligence Checks:
- INSM has $1.15B in cash and short term investments. This is enough to cover its annual cash burn of $627.58M.
- There are more short-term assets than short-term liabilities on the INSM balance sheet.
- There are more short-term assets than long-term liabilities on the INSM balance sheet.
- INSM has cash burn of 627575000. It has enough cash and short-term investments to cover this for at least one year.
Failed Financial Due Diligence Checks:
- INSM has a relatively high debt to equity ratio of 2.07.
- INSM profit margin has gone up by 2.25 percentage points in the past year, but the company is still unprofitable.
- Total INSM debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Insmed stock, according to analysts?
Out of 14 Equities analysts who give recommendations on INSM, the consensus analyst rating on INSM is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest INSM Analyst Upgrades/Downgrades
Eliana Merle, a top 14% analyst from Barclays maintains INSM with a strong buy rating and lowers their INSM price target from $237.00 to $207.00, on Sep 30, 2026.
Andrea Newkirk, a top 24% analyst from Goldman Sachs reinstates INSM with a strong buy rating and announces their INSM price target of $188.00, on Sep 24, 2026.
Adam Walsh, a bottom 8% analyst from Roth Capital reiterates INSM with a strong buy rating and lowers their INSM price target from $212.00 to $198.00, on Sep 15, 2026.
Jessica Fye, a top 9% analyst from JP Morgan maintains INSM with a strong buy rating and lowers their INSM price target from $179.00 to $175.00, on Aug 10, 2026.
Danielle Brill, a top 12% analyst from Truist Securities reiterates INSM with a strong buy rating and raises their INSM price target from $185.00 to $195.00, on Aug 10, 2026.
Truist Securities's Danielle Brill raised their price target on Insmed (NASDAQ: INSM) by 5.4% from $185 to $195 on 2026/08/10. The analyst reiterated their Strong Buy rating on the stock.
Insmed reported its Q2 2026 earnings.
Raising their price target, Brill attributed the "strong" results to a notable Brinsupri beat.
Management raised its revenue guidance, the analyst added.
Earnings Report
For Q2 2026, Insmed reported:
- EPS of $(0.52), which beat the Zacks Consensus Estimate of $(0.69) and Q2 2025's $(1.70).
- Revenue of $425.5M, which beat the Zacks Consensus Estimate of $389.7M and was up 296% Y/Y.
For FY 2026, management guided:
- Brinsupri revenue of $1.25B to $1.4B, up from the prior $1B+.
Chair & CEO Will Lewis commented: "Our team delivered tremendous results in the second quarter of the year, reflecting our operational excellence and positioning for the future.
"The U.S. BRINSUPRI launch continues to be met with significant enthusiasm and demand from patients and physicians.
"Additionally, we were pleased to report positive data from our ongoing open-label extension study of TPIP in PAH, reinforcing TPIP's potential to become the prostanoid of choice.
"Looking ahead, our focus is on building upon the early success of the BRINSUPRI launch, preparing to execute on the potential ARIKAYCE label expansion in the U.S. and Japan, progressing our Phase 3 TPIP programs across four large indications, and advancing our multiple early-stage pipeline candidates.
"As a result of our team's significant efforts, we are raising our peak revenue estimates for both BRINSUPRI and TPIP.
"We now expect that our three lead programs will generate more than $14 billion in combined peak sales.
"This ambitious yet achievable objective reflects our team's proven ability to execute and the opportunity to improve the lives of hundreds of thousands of patients worldwide."
You can dive deeper into what analysts are saying on the Insmed stock forecast page.
INSM Technical Indicators
INSM Growth Metrics
Last year, INSM revenue was $1.52B. During the past 5 year, INSM's revenue has gone up by 54.3% per year. This was faster than the Biotechnology industry average of 29.28%.
Dig into INSM's earnings and revenue performance here.
Who is buying/selling INSM?
In the last year, insiders at INSM have sold more shares than they have bought.
David R. Brennan, Director of INSM, was the latest INSM insider to sell. They sold $3,100,000.00 worth of INSM shares on Sep 9, 2026.
Research more about who owns INSM stock here.
Does INSM stock generate passive income?
No, Insmed doesn't provide an income stream by paying out dividends.
What do other investors have to say about INSM?
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your INSM buy order
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a particular dollar amount, place a limit order.
Hit the Open Trade button and your broker will place your order.
If you require more help with buying stocks on eToro, click the helpful video below:
Step 6: Get updates on your investment in INSM
Now that you own some INSM shares, you'll want to stay up-to-date on your shares.
Add INSM to a watchlist to keep tabs on your INSM stock.
INSM Feed
How to Buy Stock in Insmed
To reiterate, here are the 6 steps you need to take to buy Insmed stock right now:
- Figure out where to buy Insmed stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Analyze Insmed stock
- Place your INSM buy order
- Get updates on your investment in INSM
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to get notifications regarding your investment in Insmed, create your watchlist below.
Related Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.